pomalidomide
pomalidomide: sourced relationships with 1 company · 49 clinical trials tracked · 1 FDA decision.
pomalidomide evidence translation
What we can confirm
1 FDA record · 49 tracked trials
What it means
What to watch
Prepared research question
How could pomalidomide → RDY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 8 study sponsors
Related indications
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| DR REDDYS LABORATORIES LTD (RDY) Reported 2026-08-31 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (49)showing 10 most recent
An Open-Label Phase Ib, Multicenter Study To Evaluate The Safety And Efficacy Of Belantamab Mafodotin Plus Cevostamab And Pomalidomide In Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Primary endpoint: Recommended Phase 2 Dose (RP2D)
A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)
Primary endpoint: Safety Run-In: Number of Participants With Adverse Events (AE)s
TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)
Primary endpoint: Frequency and severity of treatment emergent adverse events (TEAEs)
A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)
Primary endpoint: Minimal residual disease (MRD) negativity
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.
Primary endpoint: To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM.
An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab Plus Carfilzomib Versus Standard of Care Combination Regimens in Patients With Relapsed/Refractory Multiple Myeloma
Primary endpoint: Occurrence of Treatment Emergent Adverse Events (TEAEs)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma
Primary endpoint: Dose-Limiting Toxicities (DLT)s of ABBV-453
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
Primary endpoint: Progression Free Survival (PFS)
A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or in Combination With Pomalidomide for Multiple Myeloma
Primary endpoint: Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Primary endpoint: Progression-Free Survival (PFS)
Frequently asked questions
Which companies have sourced relationships with pomalidomide?
pomalidomide has dated SEC/FDA relationship records for DR REDDYS LABORATORIES LTD.
How many clinical trials involve pomalidomide?
BioSniper tracks 49 clinical trials involving pomalidomide.
What is pomalidomide's latest FDA decision?
The most recent tracked FDA decision for pomalidomide is Approval, dated August 31, 2026.